DRUG & THERAPEUTICS LETTER A Quarterly Bulletin from Drug Information Unit (DIU) Department of Clinical Pharmacology Tribhuvan University Teaching Hospital Institute of Medicine, Maharajgunj, Kathmandu ________________________________________________________________ _______ January - March 2007 ______________________________________________________________________ What can be done about hepatitis B? Drug induced pancreatitis. Drugs and gingival bleeding.
of virus. The earliest serological marker
Drug Information Unit (DIU), TUTH. What can be done about hepatitis B?
serum transaminase levels can rangefrom around 3-fold to over 100-fold.
hepatitis B virus and are therefore at riskof developing chronic liver disease.
In about 95% of adults, acute infectionresolves
transmission globally is infection during
those infected during early childhood.
antibody to this antigen (anti-HBs) in the
Failure to clear the hepatitis B virus can
lead to chronic infection. This is definedas infection that continues for more than6 months with persistence of HBsAg,
dose of virus, the shorter this duration.
hepatitis B core antigen (anti-HBc).
During this period, patients may feelunwell,
Up to 20% of patients with chronichepatitis progress to cirrhosis, of whom
Consensus Conference on Hepatitis B.
Liver Dis 2004;8:255-66. 5. Ganem D, Prince AM. Hepatitis B
virus infection-natural history and clinical
blood. It is therefore important to avoid
patients with cirhosis type B. Hepatology
body fluids. Injecting drug users shouldalso avoid sharing needles, syringes or
Brief Information Drug induced pancreatitis
Hepatitis B vaccine is highly effective at
(ideally within 48 hours) after exposure,
inhibitors, NSAIDs, aminosalicylates (mesalazine, sulfasalazine), angiotensin
II receptor antagonists. Individual drugs
treating chronic hepatitis B infection is to
individuals. In all individuals, the ideal
agents. There is insufficient informationavailable on the course of the disease
References 1-Drug and Therapeutics Bulletin, vol 2-WHO, 2002.Hepatitis B
2002(online).Department ofCommunicable Diseases Surveillanceand Response. Available:
http://www.who.int/csr/disease/hapatitis/Hapatitis B _whocdscsrlyo2002_2.pdf
Drugs and gingival bleeding
cause an erythematous reaction whichcan result in gingival bleeding.
Bleeding gums are usually the result ofplaque-induced
result from direct trauma, viral, fungal or
rapid destruction of periodontal tissues,
erythematosus. Although it is a relatively
have adverse effects that may directly or
gingiva or opportunistic infections. Drug Information Unit (DIU), TUTH
Patients taking anticoagulants such aswarfarin or heparin may develop gingival
Letter: Question answering services.
dependent on the level of oral hygieneand the length or time the patient has
-Study on Adverse Drug Reactions:
phenytoin, cyclosporin and nifedipine.
drug, type of reactions, outcome andany sequelae from the reaction. The
The use of antibiotics (both systemically
steroids and other drugs which allow theovergrowth
websites:http://www.teachinghospital.org.np/diu.html,http://www.iom.edu.np/diu.html
Chief Editor: Prof. Kumud Kumar Kafle Editor: Dr. Sanu Maiya Shakya. Department of Clinical Pharmacology, Drug Information Unit, Room Number: 1- 85 Doctors' Room Block, TU Teaching Hospital, P.O. Box: 3578, Maharajgunj, Kathmandu. Phone No. : 4412404 Extn 1093, E-mail: [email protected]
St. Vincent News 1280 Braeside Drive, Oakville L6J 2A4 Telephone 905 849 0777 February 2012 Principal’s Message February marks the halfway point of winter and is the beginning of our preparation for Easter with Ash Wednesday falling on the 22nd of the month. As we prepare for Lent again this year Mr. Oswald, our Catholic School council Chair and I will be presenting to all students prio
This press release does not necessarily reflect the opinions of ECNP FOR MEDICAL MEDIA Five Scientific Posters Supporting the Efficacy and Tolerability of Once-Daily Lurasidone – A New Atypical Antipsychotic treatment for Adults with Schizophrenia Barcelona, 9 October, 2013 – On the occasion of the 26th European College of Neuropsychopharmacology Congress (ECNP), w